-
More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported in JAMA Network Open
This class of drugs, called GLP-1 (glucagon-like peptide-1) agonists, are being investigated for an array of side effects, as they are used to treat diabetes and help with weight loss
Chem Biodivers 21(4):e202302005
The body may push back toward a previous weight range
Although CMS sought to phase out these arrangements during the Trump administration in 2017, the Biden administration resumed approval of DSHPs and DSIPs in several states, including New York Arizona, California, Hawaii, Massachusetts, North Carolina, Oregon and Washington